Accutane’s active ingredient is isotretinoin, a synthetic form of vitamin A (specifically, 13-cis-retinoic acid) that remains the single most effective treatment for severe acne. The original brand name Accutane was discontinued in 2009, but generic isotretinoin capsules contain the same active molecule along with inactive ingredients like soybean oil, beeswax, and gelatin that help the body absorb it. What makes the drug so powerful, and so carefully regulated, goes well beyond its ingredient list.
What Isotretinoin Actually Is
Isotretinoin belongs to the retinoid family, a group of compounds related to vitamin A. Your body naturally produces small amounts of retinoic acid from dietary vitamin A, and retinoids play roles in cell growth, immune function, and skin turnover. Isotretinoin is a specific geometric arrangement of retinoic acid, and when taken orally in capsule form, it circulates through the bloodstream and reaches oil-producing glands in the skin at concentrations far higher than anything the body makes on its own. The drug has been in clinical use since the early 1980s, and for nearly all of that time, only one crystal form of isotretinoin was used in commercial capsules. Researchers have since discovered additional crystal forms that dissolve differently and may offer higher absorption, though these have not yet replaced the original formulation in most markets.
How It Shuts Down Acne at the Source
Acne is driven by four overlapping problems: overactive oil glands, clogged pores, bacterial overgrowth, and inflammation. Most acne treatments target one or two of these. Isotretinoin hits all four, which is why it works where other drugs fail. A large network meta-analysis of 221 randomized trials found oral isotretinoin to be the most effective pharmacological treatment for acne, outperforming every combination of topical antibiotics, retinoids, and benzoyl peroxide.
The drug’s most dramatic effect is on the sebaceous glands, the tiny oil factories attached to hair follicles. Isotretinoin triggers a protein called p53 inside sebaceous gland cells, which activates pathways that push those cells toward programmed death and suppresses their ability to produce sebum. One study confirmed that isotretinoin treatment raised p53 levels in the skin and sebaceous glands of acne patients, and that the resulting signaling cascade explained both the therapeutic shrinkage of oil glands and many of the drug’s side effects.
Calming Inflammation From the Inside
Isotretinoin does not just dry up oil. It also dials down the immune system’s overreaction to acne bacteria. In people with acne, immune cells called monocytes tend to overreact to the skin bacterium Cutibacterium acnes (formerly Propionibacterium acnes) by producing large amounts of inflammatory signaling molecules. Isotretinoin reduces this response by lowering the expression of a receptor called TLR-2 on monocytes, which is part of the alarm system that detects bacteria. In one study, monocytes from acne patients secreted significantly less of several key inflammatory molecules after as little as one week on isotretinoin, and the reduction persisted for at least six months after treatment ended.
More recent research has filled in additional details. After about eight weeks of isotretinoin treatment, levels of IL-8, IL-36, and a molecule called TWEAK all dropped significantly, each of which plays a role in recruiting immune cells to inflamed skin and keeping the inflammation cycle going. Separately, isotretinoin has been shown to reduce the movement of neutrophils and monocytes toward inflamed areas by suppressing TLR-2, and to lower systemic levels of inflammatory cytokines including TNF-α, IL-17, and others.
Reshaping the Skin’s Bacterial Community
Because isotretinoin shrinks sebaceous glands and cuts sebum output, it fundamentally changes the environment that skin bacteria depend on. The effect on C. acnes specifically is dramatic: one study found that isotretinoin depleted C. acnes by roughly 37-fold, with a more moderate reduction in staphylococcal species as well. But the story is more nuanced than simply killing off bacteria. Whole-genome sequencing of follicular bacteria from acne patients before, during, and after isotretinoin treatment showed that treatment success at 20 weeks correlated with specific shifts in C. acnes strain diversity, not just overall bacterial counts. Patients who responded well showed increased diversity among certain C. acnes strain clusters, and the drug significantly reduced bacterial metabolic pathways linked to growth and survival in the follicle. In other words, isotretinoin does not just reduce acne bacteria; it selectively reshapes which strains survive and how actively they can function.
Why the Capsule Formulation Matters
Isotretinoin is notoriously hard for the body to absorb. It dissolves poorly in water, and the original capsule formulation relies heavily on dietary fat to get the drug into the bloodstream. If you take a conventional isotretinoin capsule on an empty stomach or with a low-fat meal, absorption drops substantially. That is why prescribers have long told patients to take each dose with a meal containing a reasonable amount of fat.
A newer formulation uses micronization technology, which reduces the drug particles to a much smaller size and pairs them with a lipid-based carrier system. The result is roughly a two-fold or greater increase in absorption compared with the original capsule, without needing high-fat food intake. This means lower administered doses can achieve comparable blood levels, and the dose-to-dose variability shrinks because absorption no longer swings with what you ate for lunch. Not all generics use this technology, so the specific brand or generic your pharmacy dispenses can affect how consistently the drug is absorbed.
Side Effects That Follow From the Mechanism
Most of isotretinoin’s side effects are predictable consequences of shrinking oil glands throughout the body. Sebaceous glands are everywhere, not just on the face, so turning down their output affects the lips, nasal passages, eyes, and skin generally. Dry, cracked lips are nearly universal. Dry skin, nosebleeds, and sensitivity to sunlight are extremely common.
Eye Dryness and Meibomian Gland Changes
The eyes have their own oil-producing glands called meibomian glands, which line the eyelids and contribute an oily layer to the tear film that prevents tears from evaporating too quickly. Isotretinoin affects these glands just as it affects sebaceous glands elsewhere. One study found substantial deterioration in meibomian gland function during treatment, with improvement after the drug was stopped. A separate pilot study confirmed that isotretinoin may alter meibomian gland structure and cause an evaporative type of eye dryness. If you already have dry eyes or wear contact lenses, this is worth discussing with your prescriber before starting treatment.
Lipid and Liver Changes
Isotretinoin tends to push blood lipids in unfavorable directions. Triglyceride levels rise, total cholesterol and LDL cholesterol go up, and HDL cholesterol (the protective kind) goes down. This pattern has been documented since the 1980s and is the reason blood work is monitored during treatment. An early landmark study found that mean triglyceride levels rose significantly in both men and women on the drug. A more recent systematic review confirmed that treatment leads to meaningful increases in LDL, total cholesterol, triglycerides, and liver enzymes, with a decrease in HDL. A separate retrospective study found statistically significant increases in total cholesterol and triglycerides over the course of treatment, though liver enzyme increases were generally modest and stayed within normal range. For most patients these shifts reverse after stopping the drug, but for some they may not, a point covered further below.
Musculoskeletal Concerns in Younger Patients
Because retinoids influence bone and cartilage development, there has been long-standing concern about isotretinoin’s effects on growing bones. A literature review examining premature closure of growth plates found that the risk appears linked to higher doses taken over months to years, as in childhood cancer treatment, rather than the standard acne doses most teenagers receive. However, isolated cases of growth plate changes have been reported even at typical acne-treatment doses, so the possibility cannot be ruled out entirely. A clear cause-and-effect relationship between standard-dose isotretinoin and premature growth plate closure has not been established.
The Birth Defect Risk and How It Is Managed
Isotretinoin is one of the most potent teratogens in routine medical use. Exposure during pregnancy carries an estimated 20 to 35 percent risk of serious birth defects, including malformations of the skull and face, the heart, the brain, and the thymus. The drug causes these defects by triggering cell death and halting cell division in developing tissues at critical stages of fetal growth. There is no safe dose during pregnancy. Even brief exposure early in pregnancy can be devastating.
Because of this risk, the United States operates a mandatory program called iPLEDGE that regulates every step of isotretinoin distribution. Patients who can become pregnant must use two forms of contraception or commit to abstinence, take monthly pregnancy tests, and have their prescriptions filled within a narrow window after each negative test. Prescribers and pharmacies must also register. Similar programs exist in Europe and elsewhere, though the specific requirements vary. A comparative review across four continents found that even stringent risk management programs have not fully eliminated fetal exposures, suggesting the programs work best as one layer of protection rather than a guarantee.
The Unresolved Psychiatric Question
Few topics in dermatology generate as much anxiety as the question of whether isotretinoin causes depression or suicidal thoughts. Case reports linking the drug to psychiatric symptoms have accumulated since the 1980s, and the FDA requires a warning on the label. But the evidence from controlled studies has been frustratingly ambiguous. A widely cited review concluded that despite numerous case reports, there is no clear proof of a causal link between isotretinoin and depression or suicide, while acknowledging that a rare, unpredictable reaction in certain individuals remains possible.
A separate review took a somewhat different tone, noting that many studies did demonstrate increased risk of depression and attempted suicide following treatment, and that patients with bipolar disorder appeared especially vulnerable to symptom flares. A few studies also suggested a connection to psychosis, potentially through retinoid effects on dopamine signaling. The difficulty is that severe acne itself is strongly associated with depression, low self-esteem, and social withdrawal, so untangling the drug’s psychiatric effects from the disease’s psychological burden is genuinely hard. Most dermatologists monitor mood throughout treatment and take any new psychiatric symptoms seriously, regardless of whether a definitive causal mechanism has been proven.
Dosing, Cumulative Targets, and Relapse
Isotretinoin is typically prescribed based on body weight, and treatment courses usually last five to seven months. Dermatologists have traditionally aimed for a cumulative dose of at least 120 to 150 milligrams per kilogram of body weight, based on the belief that reaching this threshold minimizes the chance of acne returning after the course ends. The evidence on this point is more complicated than the rule of thumb suggests.
One study found that patients who received a cumulative dose of 220 mg/kg or more had a relapse rate of about 27 percent, compared with roughly 47 percent in those who received less. That supports the “more is better” idea. But a randomized controlled trial directly comparing 120 mg/kg and 150 mg/kg cumulative doses found similar relapse rates at 12 months after stopping treatment, about 27 and 32 percent respectively, with no statistically significant difference. Another study concluded that neither daily nor cumulative dose influenced relapse, as long as treatment continued for at least two months after acne had fully cleared. The practical takeaway is that the total dose matters less than making sure treatment continues long enough for the skin to fully settle before stopping.
Why Some People React Differently
Not everyone’s body handles isotretinoin the same way, and genetics play a meaningful role. A pharmacogenetic study followed patients who had unusually large triglyceride spikes during isotretinoin treatment and checked in on them about four years later. These “hyperresponders” were far more likely to have persistent high triglycerides, high cholesterol, excess abdominal fat, and elevated insulin levels long after finishing the drug. The lipid response was closely tied to variations in the apolipoprotein E gene. Patients whose parents had high triglycerides were also more likely to be hyperresponders. This suggests that the way your body metabolizes fats is a built-in risk factor for isotretinoin’s metabolic side effects, and that the lipid shifts seen during treatment may in some cases foreshadow a longer-term metabolic profile rather than being a temporary nuisance that fully reverses when the drug stops.
There is also the question of treatment resistance. A small percentage of patients do not respond adequately to a full course, or relapse quickly after finishing. The reasons are not fully understood, but individual differences in drug absorption, skin biology, and hormonal profiles all contribute. The micronized formulation mentioned earlier may help patients whose poor absorption was limiting the drug’s effectiveness, but it does not solve every case of resistance.
Tetracyclines and Other Drug Interactions
One contraindication that trips people up is the combination of isotretinoin with tetracycline-class antibiotics like doxycycline or minocycline. Tetracyclines are commonly prescribed for acne, and patients sometimes arrive at an isotretinoin prescription after months on one of these antibiotics. Taking both together increases the risk of a condition called pseudotumor cerebri, a dangerous buildup of pressure inside the skull that mimics the symptoms of a brain tumor. Prescribers typically stop tetracyclines before starting isotretinoin, and the two should not overlap. Vitamin A supplements should also be avoided during treatment, since isotretinoin is itself a vitamin A derivative and adding more raises the risk of vitamin A toxicity.
Long-Term Outcomes After Treatment Ends
One of isotretinoin’s most appealing features is that its effects often outlast the treatment course by years. Sebum production stays reduced for a prolonged period after the drug leaves the body, and many patients enjoy lasting remission. The anti-inflammatory changes in immune cells have been shown to persist for at least six months post-treatment. Beyond acne clearance and reduced oil production, there has been little strong evidence of lasting harmful side effects in most patients. The exception, as covered above, is in individuals genetically predisposed to metabolic shifts, where lipid abnormalities during treatment may signal a broader tendency toward metabolic syndrome. For the vast majority of patients, though, the side effects are reversible, and the acne improvement is durable enough that many consider it the closest thing dermatology has to a cure for severe acne.